BAX 802 in CHA With Inhibitors

Stopped Takeda has determined that the benefit/risk profile does not support continuation of the surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population.

Conditions

• Hemophilia A

Interventions

• BIOLOGICAL: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

Sponsor

Baxalta now part of Shire

Collaborators

• [object Object]